Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

BACKGROUND: This phase I/II trial evaluated the maximum tolerated dose (MTD) and pharmacokinetics of afatinib plus temozolomide as well as the efficacy and safety of afatinib as monotherapy (A) or with temozolomide (AT) vs temozolomide monotherapy (T) in patients with recurrent glioblastoma (GBM). M...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Reardon, David A., Nabors, Louis B., Mason, Warren P., Perry, James R., Shapiro, William, Kavan, Petr, Mathieu, David, Phuphanich, Surasak, Cseh, Agnieszka, Fu, Yali, Cong, Julie, Wind, Sven, Eisenstat, David D.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4483093/
https://ncbi.nlm.nih.gov/pubmed/25140039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou160
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados